Absorption, Distribution, Metabolism, and Excretion of [(14)C]-Volixibat in Healthy Men: Phase 1 Open-Label Study

BACKGROUND AND OBJECTIVES: Volixibat is a potent inhibitor of the apical sodium-dependent bile acid transporter in development for the treatment of nonalcoholic steatohepatitis. This phase 1, open-label study investigated the absorption, distribution, metabolism, and excretion of [(14)C]-volixibat i...

Descripción completa

Detalles Bibliográficos
Autores principales: Siebers, Nicholas, Palmer, Melissa, Silberg, Debra G., Jennings, Lee, Bliss, Caleb, Martin, Patrick T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794849/
https://www.ncbi.nlm.nih.gov/pubmed/28702877
http://dx.doi.org/10.1007/s13318-017-0429-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794849/
https://www.ncbi.nlm.nih.gov/pubmed/28702877
http://dx.doi.org/10.1007/s13318-017-0429-7

Ejemplares similares